

The thrombopoietin/MPL axis is activated in the *Gata1* low mouse model of myelofibrosis and is associated with a defective RPS14 signature

Maria Zingariello¹, Laura Sancillo², Fabrizio Martelli³, Rosa Alba Rana², Anna Rita Migliaccio^{4,5}

¹ Unit of Microscopic and Ultrastructural Anatomy, Dept of Medicine, University Campus Bio-Medico Rome, Italy

² Dept of Medicine and Ageing Sciences, University G. d'Annunzio, Chieti-Pescara, Italy

³ Hematology/Oncology and Molecular Medicine, Istituto Superiore di Sanità, Roma, Italy

⁴ Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai (ISMMS), New York, NY, USA

⁵ Dept of Biomedical and Neuromotorial Sciences, Alma Mater University, Bologna, Italy

Myelofibrosis is characterized by hyperactivation of thrombopoietin signaling which induces a RPS14 deficiency that de-regulates GATA1 in megakaryocytes by hampering its mRNA translation. Since mice carrying the hypomorphic *Gata1* mutation, which reduces the levels of *Gata1* mRNA in megakaryocytes, develop myelofibrosis¹ (Zingariello M. et al. 2015), we investigated whether the thrombopoietin axis is hyperactive in this model. *Gata1* low mice contained 2-times more *Tpo* mRNA in liver and TPO in plasma than wild-type littermates. Furthermore, *Gata1* low LSKs expressed levels of *Mpl* mRNA (5-times greater than normal) and protein (2-times lower than normal) similar to those expressed by LSKs from TPO-treated wild-type mice. *Gata1* low marrow and spleen contained more JAK2/STAT5 than wild-type tissues, an indication that these organs were reach of TPO-responsive cells. Moreover, treatment of *Gata1* low mice with the JAK inhibitor ruxolitinib reduced their splenomegaly. Also in *Gata1* low mice activation of the thrombopoietin/MPL axis was associated with a RSP14 deficiency and a discordant microarray ribosome signature (reduced RPS24, RPS26 and SBDS expression). Finally electron microscopy revealed that *Gata1* low megakaryocytes contained poorly developed endoplasmic reticulum with rare polysomes. In summary, *Gata1* low mice are a bona-fide model of myelofibrosis which recapitulates the hyperactivation of the TPO/MPL/JAK2 axis observed in megakaryocytes from myelofibrotic patients.

[1] A novel interaction between megakaryocytes and activated fibrocytes increased TGF-beta bioavailability in the GATA 1 low mouse model of mielofibrosys. Am J blood Res 2015 Dec 25; 5 (2): 34-61

Keywords

MPL, Thrombopoietin (TPO), JAK2, GATA1, megakaryocytes